Emory Healthcare, the largest healthcare system in the state of Georgia with 11 hospitals and 250 provider locations, has launched a new Osseointegration Program with Integrum’s OPRA™ Implant System. The program is led by Nickolas Reimer, MD, and Shervin Oskouei, MD, specialists in orthopaedic oncology and orthopaedic surgery.
Integrum’s OPRA™ Implant System is the only FDA-approved, bone-anchored prosthetic solution available in the United States. OPRA™ Implant System consists of an anchorage element (fixture) and a skin penetrating device (abutment). The fixture is surgically inserted into the femur, and after a healing time of several months, the abutment is connected to the fixture. The prosthetic leg is then attached directly to the abutment via the OPRA™ Axor™, a prosthetic connection and safety device.
“We’re excited to introduce this new technology to our patients to advance their limb function and improve their quality of life,” says Scott D. Boden, MD, vice president for business innovation for Emory Healthcare and professor and chair of the Department of Orthopaedics, Emory University School of Medicine.
Over the past years, the introduction and consideration of osseointegration as a viable option for specific amputees within the limb loss community has continued to establish itself in the U.S. market. This rapidly developing treatment for amputee care gained a considerable boost when the FDA awarded Integrum an HDE approval for the OPRA™ Implant System in July 2015. The subsequent years have seen the Department of Defense, University of California San Francisco, Johns Hopkins Hospital, and Presbyterian St.Luke’s Medical Center Hospital adopt the OPRA™ Implant System.
Blake Pokress, Vice President of Integrum Inc added, “We are excited to see Emory Healthcare adopt our technology through our partners at Onkos Surgical. We strive to make this remarkable technology accessible for individuals living with limb loss in the United States, and this is another step towards that”.
To make an appointment at Emory Orthopaedics & Spine Center, call 404-778-3350.
The information in this press release is information that Integrum AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the contact person set out below, at 14:30 CET on August 26th, 2020.Integrum AB is listed on Nasdaq First North in Stockholm. Erik Penser is the Company´s Certified Adviser.
For further information, please contact:
Maria Lopez, CEO
Cell: 0708-46 10 69
Blake Pokress, VP North America
Erik Penser Bank AB
Tel. +46 8 463 8000